SCHEMBL14428352

SCHEMBL14428352

Cc1cccc2ccc(-c3ccncc3)nc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 5/20 0.53
NPC1 O15118 2/20 0.53
CYP2C9 P11712 2/20 0.53
CYP1A2 P05177 1/20 0.53
CYP3A4 P08684 1/20 0.53
CYP2D6 P10635 1/20 0.53
CYP2C19 P33261 1/20 0.53
RAB9A P51151 1/20 0.53
MGAM O43451 1/20 0.49
GAA P10253 1/20 0.49
SI P14410 1/20 0.49
MGAM2 Q2M2H8 1/20 0.49
PFKFB3 Q16875 1/20 0.47
TGFBR1 P36897 1/20 0.44
TSHR P16473 2/20 0.42
KDM4E B2RXH2 2/20 0.41
LMNA P02545 2/20 0.41
USP2 O75604 1/20 0.41
ALDH1A1 P00352 1/20 0.41
POLB P06746 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8888541 0.85 PARP1 (0.54) ARNPC1RAB9ATGFBR1TSHR
SCHEMBL19618096 0.82 AR (0.59) ARCYP1A2RAB9APFKFB3TGFBR1
SCHEMBL20670996 0.81 MEN1 (0.54) ARNPC1CYP3A4RAB9ATGFBR1
SCHEMBL19618104 0.79 AR (0.56) ARCYP1A2PFKFB3TGFBR1KDM4E
SCHEMBL29496334 0.79 RAB9A (0.53) ARNPC1CYP2C9CYP1A2CYP3A4
SCHEMBL30590014 0.79 NPC1 (0.53) ARNPC1CYP2C9CYP1A2CYP3A4
SCHEMBL1034290 0.79 CYP3A4 (0.53) ARNPC1CYP2C9CYP1A2CYP3A4
SCHEMBL28722905 0.79 RAB9A (0.53) ARNPC1CYP2C9CYP1A2CYP3A4
SCHEMBL17430076 0.74 AR (0.43) ARNPC1CYP3A4RAB9AGAA
SCHEMBL17899346 0.74 NOTUM (0.58) ARNPC1CYP2C9CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070191372-A1 Dna-targeted benzotriazine 1,4-dioxides and their use in cancer therapy AUCKLAND UNISERVICES LIMITED (NZ) 2007-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191372-A1 Dna-targeted benzotriazine 1,4-dioxides and their use in cancer therapy HIF1AN, HIF1A, HYOU1 AR 1053/4885NPC1 2831/4885CYP2C9 2623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.